US 12,031,145 B2
Cancer therapy
Tuuli Ranki, Helsinki (FI); Sari Pesonen, Helsinki (FI); Petri Priha, Helsinki (FI); Erkko Ylösmäki, Helsinki (FI); Vincenzo Cerullo, Helsinki (FI); and Beatriz Martins, Helsinki (FI)
Assigned to Valo Therapeutics OY, Helsinki (FI)
Appl. No. 16/982,984
Filed by Valo Therapeutics Oy, Helsinki (FI)
PCT Filed Mar. 19, 2019, PCT No. PCT/EP2019/056770
§ 371(c)(1), (2) Date Sep. 21, 2020,
PCT Pub. No. WO2019/179979, PCT Pub. Date Sep. 26, 2019.
Claims priority of application No. 1804468.5 (GB), filed on Mar. 21, 2018; and application No. 1814866.8 (GB), filed on Sep. 13, 2018.
Prior Publication US 2021/0332382 A1, Oct. 28, 2021
Int. Cl. C12N 15/86 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C12N 7/00 (2006.01)
CPC C12N 15/86 (2013.01) [A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C12N 7/00 (2013.01); C12N 2710/10332 (2013.01); C12N 2710/10343 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A modified adenovirus comprising:
at least one polypeptide attached covalently or non- covalently onto the viral capsid without having been genetically encoded by said adenovirus, wherein the at least one polypeptide comprises:
i) VFGIELMEVDPIGHLYIFAT [SEQ ID NO:1];
ii) YLAMPFATPMEAELARRSLA [SEQ ID NO:2]; or
iii) a polypeptide that is at least 90% identical to SEQ ID NO: 1 or SEQ ID NO: 2;
a deletion of the 14.7 k gene;
a transgene encoding CD40L; and
a transgene encoding OX40L situated in the E3 region of the modified adenovirus.